All In Biotech

Drug Trial Radar · NCT06902844

Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

A Study of Equecabtagene Autoleucel Injection (Eque-cel) in the Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Apr 5, 2025

Primary completion

Oct 31, 2027

Study completion Jan 10, 2028

Sponsor

Lead sponsor
Tongji HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Nanjing IASO Biotechnology Co., Ltd.
First posted
Mar 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed /refractory systemic lupus erythematosus (SLE).

Conditions

  • Systemic Lupus Erythematosus (SLE)
  • Lupus Nephritis (LN)

Interventions

  • Equecabtagene Autoleucel InjectionDrug

    dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response rate of SRI-4 at 6 months after Eque-cel infusionTime frame: 6 months post Eque-cel infusion.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.